Burney Co. Has $1.55 Million Position in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)

Burney Co. cut its position in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 52.4% during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 10,871 shares of the specialty pharmaceutical company’s stock after selling 11,987 shares during the quarter. Burney Co.’s holdings in Jazz Pharmaceuticals were worth $1,554,000 as of its most recent SEC filing.

Other institutional investors have also recently added to or reduced their stakes in the company. Tyers Asset Management LLC raised its position in shares of Jazz Pharmaceuticals by 68.8% in the first quarter. Tyers Asset Management LLC now owns 33,456 shares of the specialty pharmaceutical company’s stock valued at $4,782,000 after purchasing an additional 13,632 shares during the period. Hancock Whitney Corp raised its position in shares of Jazz Pharmaceuticals by 6.0% in the first quarter. Hancock Whitney Corp now owns 3,988 shares of the specialty pharmaceutical company’s stock valued at $570,000 after purchasing an additional 226 shares during the period. Amundi Pioneer Asset Management Inc. raised its position in shares of Jazz Pharmaceuticals by 10.7% in the first quarter. Amundi Pioneer Asset Management Inc. now owns 410,994 shares of the specialty pharmaceutical company’s stock valued at $58,750,000 after purchasing an additional 39,812 shares during the period. Northern Trust Corp raised its position in shares of Jazz Pharmaceuticals by 5.9% in the first quarter. Northern Trust Corp now owns 408,976 shares of the specialty pharmaceutical company’s stock valued at $58,463,000 after purchasing an additional 22,890 shares during the period. Finally, Commonwealth Equity Services LLC raised its position in shares of Jazz Pharmaceuticals by 9.8% in the first quarter. Commonwealth Equity Services LLC now owns 3,246 shares of the specialty pharmaceutical company’s stock valued at $464,000 after purchasing an additional 290 shares during the period. Institutional investors and hedge funds own 90.24% of the company’s stock.

JAZZ stock opened at $128.52 on Thursday. The company has a debt-to-equity ratio of 0.63, a current ratio of 3.15 and a quick ratio of 3.01. Jazz Pharmaceuticals PLC has a one year low of $113.52 and a one year high of $184.00. The company has a market capitalization of $7.28 billion, a price-to-earnings ratio of 10.50, a P/E/G ratio of 1.02 and a beta of 1.10.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last released its quarterly earnings results on Tuesday, May 7th. The specialty pharmaceutical company reported $3.27 EPS for the quarter, topping the Zacks’ consensus estimate of $2.83 by $0.44. Jazz Pharmaceuticals had a net margin of 24.88% and a return on equity of 27.35%. The business had revenue of $508.19 million during the quarter, compared to analysts’ expectations of $466.55 million. During the same quarter in the previous year, the company earned $2.98 EPS. The business’s quarterly revenue was up 14.3% compared to the same quarter last year. As a group, equities research analysts forecast that Jazz Pharmaceuticals PLC will post 13.24 earnings per share for the current fiscal year.

Several analysts have recently issued reports on JAZZ shares. Cantor Fitzgerald reissued a “buy” rating and issued a $185.00 price target on shares of Jazz Pharmaceuticals in a research report on Tuesday, March 26th. SunTrust Banks started coverage on shares of Jazz Pharmaceuticals in a research report on Tuesday, March 19th. They issued a “buy” rating and a $163.00 price target on the stock. Wells Fargo & Co set a $162.00 price target on shares of Jazz Pharmaceuticals and gave the company a “buy” rating in a research report on Tuesday, March 19th. Royal Bank of Canada set a $184.00 price target on shares of Jazz Pharmaceuticals and gave the company a “buy” rating in a research report on Monday, March 18th. Finally, Cowen reaffirmed a “buy” rating and set a $200.00 price objective on shares of Jazz Pharmaceuticals in a research note on Wednesday, February 13th. Two equities research analysts have rated the stock with a sell rating, four have issued a hold rating and fifteen have given a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average price target of $181.06.

TRADEMARK VIOLATION WARNING: “Burney Co. Has $1.55 Million Position in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)” was published by American Banking News and is owned by of American Banking News. If you are viewing this piece of content on another publication, it was copied illegally and republished in violation of United States & international trademark and copyright law. The original version of this piece of content can be read at https://www.americanbankingnews.com/2019/06/13/burney-co-has-1-55-million-position-in-jazz-pharmaceuticals-plc-nasdaqjazz.html.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.

See Also: What is a Futures Contract?

Institutional Ownership by Quarter for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply